Article
Characterization of clinical risk factors for enhanced molecular residual disease monitoring in resected early-stage non-small cell lung cancer.
BMC cancer - 4 Dec 2025
Shi Yunfei, Lei Youming, Liu Yinqiang, Zhao Wei, Yang Qingmei, Zhang Fujun, Bian Li, Luo Xiaoyu, Luo Kang, Li Haoyu, Liu Fanghao, Wang Tingguang, Liu Yong, Ma Ya, Yin Jiani C, Lv Guoli, Duan Jin
Abstract excerpt
BACKGROUND: Lung cancer is a leading cause of cancer mortality, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. Standard treatment for early-stage NSCLC involves surgical resection, often complemented by adjuvant therapies. This study explores the dynamics of molecular residual disease (MRD) in early-stage NSCLC, emphasizing the prognostic value of baseline clinical characteristics....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.